» Articles » PMID: 20038960

Time Course of Late Rectal Toxicity After Radiation Therapy for Prostate Cancer

Overview
Specialties Oncology
Urology
Date 2009 Dec 30
PMID 20038960
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Rectum and bladder are the crucial organs at risk for curative radiation therapy of localized prostate cancer. We analyzed the incidence, profile and time course of late rectal radiation toxicity. A total of 320 patients with T1-3 prostate cancer were treated with three-dimensional conformal radiation therapy (3D-CRT). The prescription dose was 70 Gy for T1 and T2 patients (n=230) and 74 Gy for patients with locally advanced T3 tumors (n=90). Late rectal toxicity was graded according to the Fox Chase modification of the Radiation Therapy Oncology Group (RTOG) and Late Effects Normal Tissue Task Force (LENT) criteria. The median follow-up time was 6.2 years (range 0.2-10.7 years). At 5 years, the risk for the development of grade 2 and 3 rectal toxicities was 15.6 and 7.0%, respectively. All new cases of grade 2 and 3 rectal toxicities were observed within 5 years after treatment. Prevalence of grade 2 and 3 rectal symptoms showed fluctuation with maximum at 1.5 years and the minor peak at 4.5 years. Toxicity profile changed significantly over time. The proportion of rectal bleeding within grade 2 and 3 toxicity decreased from 85% at 1.5 years to 46% at 4.5 years. Conversely, the proportion of fecal incontinence among grade 2 and 3 rectal symptoms gradually increased (0% at 1.5 years vs 27% at 4.5 years). Late rectal radiation toxicity represents a dynamic process. Rectal bleeding decreases and fecal incontinence increases over time.

Citing Articles

Relationship Between Radiation Therapy and Fecal Incontinence in Patients Treated for Localized Prostate Cancer: Results of the French ICONES Study.

Belkacemi Y, Coraggio G, Debbi K, Sirmai L, Hollande C, Rambaud E Prostate. 2025; 85(5):492-501.

PMID: 39810310 PMC: 11848960. DOI: 10.1002/pros.24852.


Assessment of rectal toxicities after radiation therapy for localized prostate cancer: experience of the Akanda Cancer Institute in Gabon.

Ndjembidouma B, James L, Meye P, Loembamouandza S, Belembaogo E, Ben-Bolie G Rep Pract Oncol Radiother. 2024; 28(5):636-645.

PMID: 38179290 PMC: 10764052. DOI: 10.5603/rpor.97507.


Rectal Radiation Dose and Clinical Outcomes in Prostate Cancer Patients Treated With Stereotactic Body Radiation Therapy With and Without Hydrogel.

Kundu P, Lin E, Yoon S, Parikh N, Ruan D, Kishan A Front Oncol. 2022; 12:853246.

PMID: 35350564 PMC: 8957858. DOI: 10.3389/fonc.2022.853246.


Utilization of Iodinated SpaceOAR Vue™ During Robotic Prostate Stereotactic Body Radiation Therapy (SBRT) to Identify the Rectal-Prostate Interface and Spare the Rectum: A Case Report.

Conroy D, Becht K, Forsthoefel M, Pepin A, Lei S, Rashid A Front Oncol. 2021; 10:607698.

PMID: 33489918 PMC: 7817609. DOI: 10.3389/fonc.2020.607698.


Moderately hypofractionated radiotherapy for localized prostate cancer: updated long-term outcome and toxicity analysis.

Tamihardja J, Schortmann M, Lawrenz I, Weick S, Bratengeier K, Flentje M Strahlenther Onkol. 2020; 197(2):124-132.

PMID: 32833036 PMC: 7840645. DOI: 10.1007/s00066-020-01678-w.